Clinical trials: Graft-vs-host Disease
Hematological Malignancies
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot…
- Trial name
- NCT00504803
- Testing
- Mesenchymal stem cell infusion
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Liege
Chronic Graft-versus-host Disease
Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease
Alefacept is a drug tht may reduce the number of T cells in circulation. This drug has been used in the treatment of psoriasis, which is a skin disorder also caused by T cells, like chronic GVHD.
- Trial name
- NCT01226420
- Testing
- Alefacept
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Dana-Farber Cancer Institute
Graft Versus Host Disease
Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD
The aim of this study is to measure local inflammatory responses in patients undergoing an allogeneic stem cell transplant and attempt to define any set of biomarkers that are significantly altered in acute or chronic skin graft…
- Trial name
- NCT02511782
- Testing
- D-SQUAME Skin Sampling Discs
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Acute Graft-versus-Host Disease
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
The purpose of this study is to compare the safety and efficacy of ECP treatment combined with high dose corticosteroids versus high dose corticosteroids alone, in the treatment of patients with newly diagnosed acute GvHD (Grades…
- Trial name
- NCT00282503
- Testing
- Methoxsalen+ECP, Methylprednisolone, Ecp
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 19 people
- Sponsor
- Mallinckrodt
Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
While hematopoietic stem cell transplant (HSCT) is an effective therapy, graft versus host disease (GVHD) is the most significant complication after HSCT.
- Conditions
- Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Solid Organ Transplant
- Trial name
- NCT05121142
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Morphea (Circumscribed Scleroderma), Sclerotic Graft-versus-host Disease (GVHD)
Study on the Treatment With Water-filtered Infrared-A (wIRA) Radiation in Patients With Morphea and Sclerotic Graft-versus-host Disease
This is a prospective, intra-individual comparative study to evaluate the effectiveness of local-water filtered infrared-A (wIRA) irradiation (applied by Hydrosun® radiator 750 for radiation at the clinic, or Hydrosun® 575home…
- Trial name
- NCT04954573
- Testing
- infrared-A (wIRA)
- Where
- 2 sites in Austria
- Volunteers
- 11 people
- Sponsor
- Medical University of Graz
Chronic Kidney Failure, Graft vs Host Disease
Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients
The incidence of efficacy failure at 12 months between two regimens.
- Conditions
- Chronic Kidney Failure, Graft vs Host Disease, Kidney Transplantation
- Trial name
- NCT00044720
- Testing
- Rapamune
- Volunteers
- 484 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Graft Versus Host Disease, Leukemia
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell and donor natural killer cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00450983
- Testing
- muromonab-CD3, natural killer cell therapy, fludarabine phosphate
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
Graft vs Host Disease
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
The addition of rituximab to prednisone for the initial treatment of chronic GVHD will increase the overall response rate, enable a more rapid and effective steroid taper.
- Trial name
- NCT00350545
- Testing
- Rituximab, Prednisone, Cyclosporine A
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Stanford University
Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Patients with acute leukemia relapsing after allotransplant and who respond to anti-leukaemia interventions are at high-risk of a second relapse.
- Conditions
- Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation, Acute Leukemia, Minimal Residual Disease
- Trial name
- NCT03297528
- Testing
- donor lymphocyte infusion
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Chronic Graft-versus-host-disease
Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease
Chronic graft-versus-host disease (cGVHD) affects 30 to 70% of Allogeneic Hematopoietic Cell Transplantation, decreases the quality of life, and increases mortality.
- Trial name
- NCT05348096
- Testing
- Low-dose ibrutinib
- Where
- Mexico
- Volunteers
- 13 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
GVHD - Graft-Versus-Host Disease, Neoplasms
Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity
Chronic graft-versus-host disease (cGVHD) is a complication that occurs in 30-40% of recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and is a major cause of late non-relapse mortality.
- Conditions
- GVHD - Graft-Versus-Host Disease, Neoplasms, Haematopoietic Stem Cell Transplantation
- Trial name
- FRONTJAK-001 (NCT06756061)
- Testing
- Prednisone + Jakavi(ruxolitinib), Prednisone
- Where
- South Korea
- Volunteers
- 88 people
- Sponsor
- Byung-Sik Cho
Maxillary Sinusitis, Sinusitis, Chronic
Balloon Sinuplasty Efficiency in Maxillary Rhinosinusitis.
This study is a prospective, randomized, placebo-controlled, double-blinded clinical study. The balloon sinuplasty treatment is compared to placebo effect in chronic or recurrent maxillary sinusitis.
- Conditions
- Maxillary Sinusitis, Sinusitis, Chronic, Sinusitis Recurrent, Eustachian Tube Dysfunction
- Trial name
- NCT04645511
- Testing
- Balloon sinuplasty of maxillary sinuses
- Where
- Finland
- Volunteers
- 120 people
- Sponsor
- Tampere University Hospital
Disorder Related to Bone Marrow Transplantation, Leukemia
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if combining busulfan with clofarabine and fludarabine can help control the disease better than the previous standard method (using busulfan and fludarabine alone) in patients…
- Conditions
- Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection
- Trial name
- NCT01471444
- Testing
- Fludarabine, Clofarabine, Busulfan
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- M.D. Anderson Cancer Center
Bronchiolitis Obliterans Syndrome
Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation
This study aims to determine whether or not early spirometric detection and management of obstructive lung disease with combined fluticasone/azithromycin/montelukast therapy (FAM) can attenuate declining lung function, prevent…
- Trial name
- NCT03072849
- Testing
- Pulmonary function testing, FAM Therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Graft Versus Host Disease, Leukemia
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00248430
- Testing
- aldesleukin, therapeutic allogeneic lymphocytes, melphalan
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Ocular Graft-versus-host Disease
A Study of Stem Cells Lenses in the coGVHD Subjects
This study is a single dose, Phase I study to evaluate the safety, tolerability, and preliminary effectiveness of Stem cells Lenses in the coGVHD Subjects. Three subject's enrollments are Expected.
- Trial name
- NCT06952114
- Testing
- Stem Cells Lenses
- Volunteers
- 6 people
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
Migraine Disorders
Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE
The primary objective of this study is to evaluate the safety and efficacy of occipital nerve stimulation (ONS) using the Boston Scientific Corporation (BSC) Precision™ System in the management of intractable chronic migraine…
- Trial name
- OPTIMISE (NCT01775735)
- Testing
- Occipital nerve stimulator
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boston Scientific Corporation
Resistant Chronic GVHD
Alefacept for Chronic Graft Versus Host Disease
Alefacept (AMEVIVE®) is an immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fcof IgG1.
- Trial name
- NCT00397332
- Testing
- Alefacept
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Diabetic Foot Ulcer
Nitric Oxide Generating Gel Dressing in Patients With Diabetic Foot Ulcers
This is a 2 part study to assess the safety and efficacy of a nitric oxide (NOx) generating dressing on chronic diabetic foot ulcers (DFU). Nitric oxide has a range of effects on the body including vasodilation and angiogenesis.
- Trial name
- ProNOx1 (NCT01982565)
- Testing
- NOx dressing, Standard of Care
- Where
- 10 sites in United Kingdom
- Volunteers
- 130 people
- Sponsor
- Edixomed Ltd